Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Compass Pathways (CMPS) - >>> The First Psychedelic Drug Stock Jumps In Debut After Upsized IPO
Investor's Business Daily
by BILL PETERS
09/18/2020
https://www.investors.com/news/compass-pathways-sees-544-million-valuation-first-psychedelic-drugs-ipo/?src=A00220&yptr=yahoo
Compass Pathways (CMPS) jumped in its first day of trading on Friday, making it the first psychedelic drug company to go public on a big U.S. exchange.
Shares surged 42% to 24.09 in the stock market today, giving the company a market cap of more than $800 million. The debut comes a day after the company announced an upsized pricing for its IPO.
The London-based company, which is researching a therapy using the main ingredient in hallucinogenic mushrooms, said in a release late Thursday that its IPO priced at $17 a share, up from initial expectations for $14-$16 announced earlier in the week.
Compass said it sold 7.5 million American Depositary Shares in the offering, for total proceeds of $127.5 million. That was also above the 6.7 million planned. Each of the 7.5 million American Depositary Shares represented 7.5 ordinary shares in the offering.
The company has also granted the underwriters of its IPO a 30-day option to buy an additional 1,125,000 American Depositary Shares, up from 1,005,000 initially.
Compass Pathways filed for the IPO late last month. Cowen, Evercore ISI and Berenberg were the joint book-running managers for the Compass Pathways IPO. Canaccord Genuity, already an active deal maker in the cannabis industry, is the lead manager.
The psychedelic drugs industry has been put into the spotlight over the past year, as more investors pour their money into startups promising treatments for a range of mental illnesses.
With that trend have come concerns about a repeat of the cannabis industry's boom and bust. Most existing drugs in the industry — like LSD, MDMA and psilocybin — aren't yet legal or patentable.
Compass Pathways' COMP360 Therapy
The company, in a filing on Monday, said would have around 34 million shares outstanding after the offering, or 35 million if the underwriters fully exercise the option. That could give the company a valuation of nearly $600 million.
Compass Pathways has developed a crystalline form of psilocybin, called COMP360, for which it has a U.S. patent. Psychedelic drug developers, if they want to be profitable, will likely have to develop novel drug compounds and drug-delivery methods, a path similar to the legal pharmaceutical industry.
The drug developer plans to use COMP360 in conjunction with therapy for treatment-resistant depression. If regulators approve, Compass plans to market it to clinics and health care providers in the U.S. and Europe.
The FDA in 2018 gave breakthrough status to COMP360. Last year, the agency also approved the Johnson & Johnson (JNJ) drug Spravato, which uses a derivative of ketamine, for treatment-resistant depression. This summer, the FDA approved Spravato for people who are actively suicidal.
Ketamine — perhaps best known as a party drug — is regularly used, legally, as an anesthetic. Therapists also use ketamine for psychedelic-assisted psychotherapy.
<<<
$PSYC September Newsletter to Feature Exclusive Interview with Retired NHL Heavy Hitter, Riley Cote
LAS VEGAS, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Global Trac Solutions, Inc. (OTCPink: PSYC) (“Global” “PSYC” or the “Company”) is pleased to announce that the September 15th edition of its Microdose Monthly newsletter will be highlighted by an exclusive interview with retired National Hockey League player and medicinal psychedelic advocate, Riley Cote.
In his four years with the Philadelphia Flyers, Cote developed a reputation throughout the NHL as one of the league’s most physically intimidating enforcers by racking up more than 50 on-ice fights and delivering countless bone chilling body checks to his opponents on a nightly basis. Off the ice, however, Cote found himself engaged in a fight with addiction and symptoms of PTSD that he was unable to gain an upper hand on and was steadily beginning to lose.
The Psychedelic Spotlight exclusive interview and article written by PSYC CEO, David Flores, dives attentively into Cote’s road to recovery post-retirement with the help of alternative medicines and therapeutic treatments, including microdosing psilocybin. The article also covers Cote’s current and ongoing venture with BodyChek Wellness which Cote has developed to help other individuals who are facing challenges similar to those he experienced overcome them and reclaim their health in the process.
Said Global Trac Solutions, Inc. CEO, David Flores: “I am incredibly grateful for this opportunity to share Riley’s story of how his mindful integration of psychedelics into his recovery process contributed to him overcoming his battle with addiction and symptoms of PTSD. In my opinion, sharing stories such as his are not only important in helping to lend credibility to the benefits of medicinal psychedelics, but also in the hope that his story may inspire others out there who may be struggling with some of the same conditions Riley was able to successfully overcome. Acknowledging that you are losing a battle with your mental health is most often the first, and most difficult, step towards recovery. And so if we in any way can help encourage or motivate individuals who may be out there struggling with their mental health to take the first step towards getting the help they need through the stories, education, and information we are providing, then we are, in my opinion, accomplishing something quite profound from a societal perspective .”
Last month, the Company announced that in response to its ability to effectively increase its production of original content focused on the emerging psychedelic industry, that it’s Microdose Monthly newsletter will be distributed to subscribers on a semi-monthly basis (15th and 25th of each month). The Company encourages those who have not done so already, to subscribe to Microdose Monthly by visiting www.psychedelicspotlight.com.
About Global Trac Solutions, Inc. (OTCPink: PSYC)
Global Trac Solutions is a diversified holding company dedicated to identifying new and emerging industries. By utilizing our years of business development expertise our diverse team of innovators continuously leverages our experience to effectively execute go-to-market strategies in order to position ourselves for rapid growth through the creation of an evolving business foundation to enhance profitability potential.
PSYC has expressed its intent and commitment to positioning itself at the forefront of the psychedelic revolution and as a resource center for discovering and understanding the latest research and business opportunities surrounding psychedelic inspired medicines. In conjunction with the FDA’s more open-minded approach to psychedelic medicines, and as several major U.S. cities continue to approve the decriminalization of psilocybin, investors are speculating that the psychedelic boom could be bigger than that of cannabis. PSYC is your source for current investment related news specific to psychedelic medicines and cutting-edge research improving overall health, moving this sector into the mainstream.
We believe in a forward-thinking approach that embraces groundbreaking new technology and innovations and through the vision of business development we intend to continue to evolve into these unchartered territories as the industry leaders of the future. We truly are the right TRAC to follow.
Forward-Looking Statements Disclaimer:
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by the following words: "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "ongoing," "plan," "potential," "predict," "project," "should," "will," "would," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements are not a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. Forward-looking statements are based on information available at the time the statements are made and involve known and unknown risks, uncertainty and other factors that may cause our results, levels of activity, performance or achievements to be materially different from the information expressed or implied by the forward-looking statements in this press release. This press release should be considered in light of all filings of the Company that are disclosed on the OTC Markets.com website.
Disclaimer: Global Trac Solutions, Inc. does not in any way encourage or condone the use, purchase, sale or transfer of any illegal substances, nor do we encourage or condone partaking in any unlawful activities. We support a harm reduction approach for the purpose of education and promoting individual and public safety. If you are choosing to use psychedelic substances, please do so responsibly.
Corporate Contact:
Global Trac Solutions, Inc. (PSYC)
http://www.globaltracsolutions.com
(702) 239-1919
info@globaltracsolutions.com
OTCPINK: PSYC
$PSYC Establishes New Partnership with Industry Leader, Microdose Psychedelic Insights
LAS VEGAS, Aug. 18, 2020 (GLOBE NEWSWIRE) -- Global Trac Solutions, Inc. (OTCPink: PSYC) (“Global” “PSYC” or the “Company”) is pleased to announce that in an effort to accelerate the Company’s development of premium industry centric content for its Psychedelic Spotlight website (www.psychedelicspotlight.com) and Microdose Monthly newsletter, PSYC has established a content development partnership with Microdose Psychedelic Insights (“Microdose”) (www.microdose.buzz), the leader in psychedelic media and events based out of Toronto, Canada.
Through this partnership with Microdose, PSYC will have the distinct ability to work in a collaborative effort with Microdose’s talented and knowledgeable content development team to produce and present original, broad-minded content that offers a unique and in-touch perspective related to the emerging space of psychedelic medicine.
Said Global Trac Solutions, Inc. CEO David Flores: “We are delighted to have established this outstanding partnership with a firm like Microdose who have such a compelling and impressive finger on the pulse of the medicinal psychedelic industry. More importantly, I am thrilled to partner and work with a company where our passion, principles, and overall vision within this industry are so perfectly aligned and the opportunity it will present to unify each of these critical aspects in producing exceptional informational and educational-focused content that I hope will contribute to the advancement of psychedelic medicines as a recognized treatment. It is also our intent to leverage this terrific opportunity to more distinctly develop our identity and expand our reach within this quickly evolving sector.”
Said Patrick Moher, Microdose Partner: “We are pleased to be aligning the team at Psychedelic Spotlight, amplify our ability to produce high quality, evidence based, original psychedelic content. We believe that collaboration is critical to create a successful industry in the long term and are excited to see where this partnership takes us.”
In addition to this partnership, the Company has also demonstrated considerable focus in recent weeks towards expanding its pool of talented and experienced freelance writers within the field of medicinal psychedelics and with the intent of increasing its production and output of original content over the next several weeks and in the months ahead.
About Global Trac Solutions, Inc. (OTCPink: PSYC)
Global Trac Solutions is a diversified holding company dedicated to identifying new and emerging industries. By utilizing our years of business development expertise our diverse team of innovators continuously leverages our experience to effectively execute go-to-market strategies in order to position ourselves for rapid growth through the creation of an evolving business foundation to enhance profitability potential.
PSYC has expressed its intent and commitment to positioning itself at the forefront of the psychedelic revolution and as a resource center for discovering and understanding the latest research and business opportunities surrounding psychedelic inspired medicines. In conjunction with the FDA’s more open-minded approach to psychedelic medicines, and as several major U.S. cities continue to approve the decriminalization of psilocybin, investors are speculating that the psychedelic boom could be bigger than that of cannabis. PSYC is your source for current investment related news specific to psychedelic medicines and cutting-edge research improving overall health, moving this sector into the mainstream.
We believe in a forward-thinking approach that embraces groundbreaking new technology and innovations and through the vision of business development we intend to continue to evolve into these unchartered territories as the industry leaders of the future. We truly are the right TRAC to follow.
About Microdose Psychedelic Insights
Microdose Psychedelic Insights aims to unlock the potential of psychedelics through Industry events, market intelligence, original, evidence-based content, strategy and community. We enable and empower society at large to make better, more mindful decisions about psychedelics and its intersection with healthcare, medicine and personal growth. We work with the industry's most influential stakeholders, some of the world's best-known brands and an unrivalled network of scientists, researchers, analysts, innovators, investors and advisors.
Contact: info@microdose.buzz
Forward-Looking Statements Disclaimer:
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by the following words: "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "ongoing," "plan," "potential," "predict," "project," "should," "will," "would," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements are not a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. Forward-looking statements are based on information available at the time the statements are made and involve known and unknown risks, uncertainty and other factors that may cause our results, levels of activity, performance or achievements to be materially different from the information expressed or implied by the forward-looking statements in this press release. This press release should be considered in light of all filings of the Company that are disclosed on the OTC Markets.com website.
Disclaimer: Global Trac Solutions, Inc. does not in any way encourage or condone the use, purchase, sale or transfer of any illegal substances, nor do we encourage or condone partaking in any unlawful activities. We support a harm reduction approach for the purpose of education and promoting individual and public safety. If you are choosing to use psychedelic substances, please do so responsibly.
Corporate Contact:
Global Trac Solutions, Inc. (PSYC)
http://www.globaltracsolutions.com
(702) 239-1919
info@globaltracsolutions.com
Info site - Psycheledic Spotlight -
https://www.psychedelicspotlight.com/
$PSYC Positions Psychedelic Spotlight for Next Phase of Growth With Strategic Updates
LAS VEGAS, Aug. 11, 2020 (GLOBE NEWSWIRE) -- Global Trac Solutions, Inc. (OTCPink: PSYC) (“Global” “PSYC” or the “Company”) is pleased to announce that within the past several days it has begun to push critical updates to the Company’s Psychedelic Spotlight website (www.psychedelicspotlight.com) in an effort to more effectively align the site with the growth initiatives and strategies it has established, and infusing it with features intended to optimize potential revenue generation capabilities over the next several months.
The Company contends that some of the most significant updates to the site were made to its homepage where its objective was to provide a more intuitive layout designed to magnify news headlines within the emerging space of psychedelic medicine, along with its own original industry-based content, and encourage a more impactful user experience for its growing number of visitors. Additionally, considerable thought and effort was focused on placing the necessary building blocks in place with the intent of ensuring the site is adequately positioned to begin incorporating potential revenue-driven opportunities within the coming months.
Said Global Trac Solutions, Inc. CEO, David Flores: “I positively view our Psychedelic Spotlight website as a continuously evolving endeavor which is why I believe it is essential for us to ensure that we have a solid foundation for it in place that is capable of sustaining and maximizing the growth and expansion that I anticipate it experiencing over the next several months. With the constant eye that I have on revenue opportunities for the website such as the sale of advertisement space and other promotional marketing opportunities, I am truly encouraged with the direction we are now moving in with the site given these critical updates we have been able to incorporate in recent weeks. I believe these updates should also provide a fairly accurate glimpse into the identity we are focused on establishing for PSYC and the specific sector of this emerging industry that we are looking to carve out for ourselves as we move forward.”
The Company contends that in addition to the visual and layout-related updates it has released for Psychedelic Spotlight, that it is also beginning to work closely with search engine optimization (SEO) and data analytic experts to continue to identify opportunities to enhance the user experience for the site as well as other related enhancements focused on increasing the site’s online presence within the expanding medicinal psychedelic community.
About Global Trac Solutions, Inc. (OTCPink: PSYC)
Global Trac Solutions is a diversified holding company dedicated to identifying new and emerging industries. By utilizing our years of business development expertise our diverse team of innovators continuously leverages our experience to effectively execute go-to-market strategies in order to position ourselves for rapid growth through the creation of an evolving business foundation to enhance profitability potential.
PSYC has expressed its intent and commitment to positioning itself at the forefront of the psychedelic revolution and as a resource center for discovering and understanding the latest research and business opportunities surrounding psychedelic inspired medicines. In conjunction with the FDA’s more open-minded approach to psychedelic medicines, and as several major U.S. cities continue to approve the decriminalization of psilocybin, investors are speculating that the psychedelic boom could be bigger than that of cannabis. PSYC is your source for current investment related news specific to psychedelic medicines and cutting-edge research improving overall health, moving this sector into the mainstream.
We believe in a forward-thinking approach that embraces groundbreaking new technology and innovations and through the vision of business development we intend to continue to evolve into these unchartered territories as the industry leaders of the future. We truly are the right TRAC to follow.
Forward-Looking Statements Disclaimer:
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by the following words: "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "ongoing," "plan," "potential," "predict," "project," "should," "will," "would," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements are not a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. Forward-looking statements are based on information available at the time the statements are made and involve known and unknown risks, uncertainty and other factors that may cause our results, levels of activity, performance or achievements to be materially different from the information expressed or implied by the forward-looking statements in this press release. This press release should be considered in light of all filings of the Company that are disclosed on the OTC Markets.com website.
Disclaimer: Global Trac Solutions, Inc. does not in any way encourage or condone the use, purchase, sale or transfer of any illegal substances, nor do we encourage or condone partaking in any unlawful activities. We support a harm reduction approach for the purpose of education and promoting individual and public safety. If you are choosing to use psychedelic substances, please do so responsibly.
Corporate Contact:
Global Trac Solutions, Inc. (PSYC)
www.globaltracsolutions.com
(702) 239-1919
info@globaltracsolutions.com
Source: Global Trac Solutions, Inc
Spravato / Esketamine - >>> J&J's ketamine-based drug drives sea change for new depression treatments
By Joe Williams
March 07, 2019
FOXBusiness
https://www.foxbusiness.com/healthcare/jj-depression-drug-approval-spurs-new-hope-for-the-field
Nasal spray developed by Johnson & Johnson may be the key to fighting treatment resistant depression
The Trump administration’s Opens a New Window. approval of Johnson & Johnson’s ketamine-based depression treatment Opens a New Window. comes as a slew of other drugmakers look to advance their own medications Opens a New Window. for the disease, driving renewed investor interest in a dormant therapeutic area, according to industry executives and experts.
But while Spravato, developed by J&J unit Janssen, is seen as a pivotal turning point in what has been a decades-long drought of new depression drugs, significant questions remains over how popular the treatment will be after the Food and Drug Administration imposed strict safety requirements for patients seeking the treatment.
The field also remains a difficult one to study and there are no assurances that any of the still experimental treatments will succeed. Botox-maker Allergan, for example, announced on Wednesday evening that its highly anticipated depression drug rapastinel failed in late-stage trials.
Still, advocates are bullish that new, safer treatments under development will soon reach patients.
“There is a lot of activity in this space, looking at drugs that work faster and work on different mechanisms completely than what has been studied before,” Sanjay Mathew, vice chair for research at Baylor College of Medicine and a member of the Anxiety and Depression Association of America, told Fox Business. “The key will be to develop equally as effective drugs without the liability.”
Of particular interest, according to VistaGen Therapeutics Inc. CEO Shawn Singh, is the data the agency used to approve Spravato. Johnson & Johnson relied on what is referred to in the industry as a randomized withdrawal study, or a trial format in which a patient first receives a drug for a specific period of time and then either stays on the existing regiment or is transferred to a placebo.
“It is definitely the case that we need more innovative clinical trial designs in order to manage down what’s often the case is a placebo effect in neuropsychiatry studies,” he said. “Not only [will] companies developing new medicines for depression and other mood related disorders benefit, but certainly patients will.”
Small biotech companies have emerged to fill the white space left by large pharmaceutical firms that largely abandoned research on new depression treatments. But with an immense market of individuals that suffer from the disease and the success of Spravato, the sector is getting renewed interest.
“You need game-changing options to really drive the business-side and Wall Street’s attention,” Singh said. “Before this approval signaling that new options are on the horizon, there really wasn’t much reason to pay attention to this space. But now there certainly is.”
VistaGen is developing its own treatment for depression that aims to address the safety concerns the FDA had in approving Spravato to allow for in-home use.
On top of the mandate that prospective users fail on at least two other medications first, the agency is requiring that patients receive the drug in a clinician’s office and are monitored for two hours after the nasal spray is administered.
As with any new treatment, the industry is also watching closely to see how much patients will ultimately pay for Spravato, which will set the bar for future drugs. While the dosage and frequency will vary by individual, most will need it twice a week for at least the first month, totaling as much as $6,785 per month for the initial phase. Depending on the response, some patients could reduce their schedule to weekly or biweekly, lowering the cost to as much as $2,540 a month.
It remains to be seen how much physicians will charge to administer the drug and monitor patients afterwards, as well as what sort of discounts will be negotiated between Johnson & Johnson and pharmacy benefit managers. In order to provide the treatment, doctors must be certified by the company and clinics must meet a strict set of guidelines.
Given the hurdles to receive the drug, the universe of depression sufferers are unlikely to take Spravato. Still, it remains the most exciting development in the field in decades.
Johnson & Johnson “is taking on these really important challenges that other people are not taking on,” said Tonix CEO Seth Lederman, which is developing a drug for post-traumatic stress disorder in military veterans. “Getting this important drug approved was not easy and not inexpensive, so I’m not sure how this will translate down into smaller psychiatry companies.”
<<<
>>> Psychedelic Medicine Stocks Capture The Attention Of Investors
Mar. 6, 2020
Includes: ACB, AMRS, ARNA, EHVVF, OGI, RVVTF, TLRY, WUHN
Seeking Alpha
by David Kugelman
https://seekingalpha.com/article/4330293-psychedelic-medicine-stocks-capture-attention-of-investors
Psychedelic medicine involves the use of psychedelic substances such as psilocybin (the chemical in magic mushrooms), MDMA, LSD, and ketamine to treat patients with mental health issues.
The big difference between psychedelic medicine and cannabis is the way in which they're used in therapy.
Mind Medicine became the first psychedelics pharmaceutical firm to go public.and involves "Shark Tank" investor Mr. Wonderful Kevin O'Leary and Canopy Growth Corp. CEO Bruce Linton.
The Center for Psychedelic and Consciousness Research at Johns Hopkins Medicine is a $17 million research center devoted to studying psychedelic medicine.
Cities like Denver, Oakland, and Santa Cruz voted to decriminalize magic mushrooms.
If you think investors made big money from cannabis stocks, you had better be ready to start buying psychedelic medicine stocks! Psychedelic medicine involves the use of psychedelic substances such as psilocybin (the chemical in magic mushrooms), MDMA, LSD, and ketamine to treat people with depression, addiction, PTSD, ADHD, and the psychological challenges posed by terminal illnesses.
The big difference between psychedelic medicine and cannabis is the way in which they're used in therapy. Psilocybin is used to enhance therapy and is not necessarily the treatment while cannabis mostly treats symptoms. The U.S. Food and Drug Administration (FDA) authorized Breakthrough Therapy Designation to both Compass Pathways' and Usona Institute's psilocybin therapy for depression in 2018. Johnson & Johnson's (NYSE: JNJ) ketamine-derived medicine, Spravato, has been available for pain relief for years. In March 2019, the FDA approved Spravato for treatment-resistant depression. This was huge, since ketamine not only has hallucinogenic properties, but is well known as a party drug by its common street names K, Special K, Kit Kat, and Jet, as well as a few others. Last September a group of private donors ponied up $17 million to start the Center for Psychedelic and Consciousness Research at Johns Hopkins Medicine, making it what's believed to be the first such research center in the U.S. and the largest research center of its kind in the world. Just as we saw with cannabis, voters in cities like Denver, Oakland, and Santa Cruz voted to decriminalize magic mushrooms.
There are several private companies like ATAI Life Sciences and COMPASS Pathways making headway in the psychedelic medicine space. Investors are looking for ways to profit, so let's take a look at a few of the publicly traded psychedelic medicine companies.
First, and most obvious, is Mind Medicine (MindMed) Inc. (NEO:MMED) (OTC:MMEDF), which became the first psychedelics pharmaceutical firm to go public. MindMed involves "Shark Tank" investor Mr. Wonderful Kevin O'Leary and Canopy Growth Corp. (NYSE:CGC) CEO Bruce Linton, so that alone has investors excited. MindMed raised $24.2 million privately before it came public March 3, 2020 on the NEO Exchange. Investors are bidding the shares up, since Canopy Growth and GW Pharmaceuticals (NASDAQ: GWPH) both delivered 1,000% plus returns for investors that bought their IPOs.
MindMed came public via a reverse merger with Broadway Gold Mining Ltd. and has traded between C$0.24 and C$0.64 with a current market cap in excess of C$115 million. At present, MindMed is preparing 18-MC, its lead development drug development program, for a Phase 2 clinical trial, planned to begin in the fourth quarter. 18-MC is a non-hallucinogenic drug candidate, based on the psychedelic substance ibogaine, which in extensive preclinical research has shown promise for helping to curb addictions. MindMed is also preparing to conduct a Phase 2 LSD microdosing clinical trial for adult ADHD, expected to begin later this year.
Here are a few words of caution on MindMed. It is very difficult for U.S. investors to buy a stock on the Canadian Neo Exchange. Many U.S. investors in search of the next big thing are snapping up shares of MMEDF on the U. S. OTC Gray Market. According to OTC Markets, Grey Market, "OTC" or "Other OTC" is a security that is not currently traded on the OTCQX, OTCQB or Pink markets. Broker-dealers are not willing or able to publicly quote OTC securities because of a lack of investor interest, company information availability or regulatory compliance. Also, MindMed filings on SEDAR reference an email address at the domain savanthwp.com. This is worth looking into, since on closing the transaction, Savant Addiction Medicine, LLC, received Multiple Voting Shares for each share of MindMed PrivateCo that it held immediately prior to completion of the transaction. Savant Addiction Medicine, LLC is currently the only holder of Multiple Voting Shares. All other former MindMed private company shareholders received Subordinate Voting Shares.
Ehave, Inc. (OTCPK:EHVVF) just announced plans to enter the $88 billion mental health market with plans to acquire 100% of PsychedeliTech, a division of Israel based Israel Cannabis Limited ("iCAN"). Ehave management believes PsychedeliTech could be a leader in the commercialization of research into psychedelics for the treatment of anxiety, depression, and other mental illnesses. Ehave, Inc. and PsychedeliTech intend to create an ecosystem to nurture the development of therapies using psychedelics. The ecosystem includes clinical trials, biosynthesis of psychedelic compounds, E-commerce, CPG'S, supply, dosage, delivery, data, conferences and business intelligence.
PsychedeliTech is also involved in the inaugural PsyTech Summit, which will take place June 14th and 15th, 2020 at the Hilton Hotel, on the Mediterranean Sea in Tel Aviv, Israel. Rick Doblin, Ph.D., Founder and Executive Director of the Multidisciplinary Association for Psychedelic Studies (MAPS) will be the gathering's keynote speaker. The landmark event will bring together scientists, innovators, regulators, investors, and advocates from around the world to expand minds to the potential of psychedelic medicine. Ehave also plans to drive researchers to its Ehave Connect mental health informatics platform. According to the Company, Ehave's Dashboard allows clinicians to make objective, data-driven decisions while keeping patients informed and engaged throughout their mental healthcare journey. Ehave's recently expanded its partnership with BurstIQ to bring its dashboard compliant with both HIPAA and GDPR standards using BlockChain technology. BurstIQ remains the only blockchain platform to receive compliance certification under SOC 2 Type 2 audit requirements.
Revival Therapeutics (CSE:RVV) (OTCPK:RVVTF) recently announced the acquisition of Psilocin Pharma Corp., which has developed production solutions for the active compound Psilocybin. Psilocin Pharma Corp. has developed 6 formulations under the Hydroxy Line including capsules, sublingual spray, gel caps, effervesce tablets, and breath strips. According to the Company, the precisely dosed formulations work with both natural and synthetically derived Psilocybin which will be targeted for clinical research and subject to eventually FDA approval in the treatment of Depression, Anxiety, Bi-polar disorder, Bulimia and Anorexia Nervosa. Psilocin Pharma also has strong relationships with specific lab partners in certain areas like Brazil, where these formulations are legally approved and plan to sell products in these jurisdictions. Interesting to note, Psilocin Pharma Corp, a company that was created just 6 days before the LOI was announced.
In April, 2019 Wuhan General Group, Inc. (OTCPK:WUHN) announced that its subsidiary MJ MedTech, Inc. created a new division dedicated to exploring opportunities in the psychedelic medicine space. The new division, M2BIO would be headed up by Wuhan's CMO, Dr. Anna Morera Lorelta. The new division, M2BIO aims to develop new therapies that will help patients who suffer from mental illness and ease the burden on healthcare systems globally. This division will be exploring additional indications for psilocybin, with the goal of bringing new therapies to market. One month later Wuhan General Group announced it had acquired a 49% interest in Cape Town, South Africa based Biodelta Nutraceuticals. According to a press release issued in July 2019, Wuhan General Group and Biodelta Nutraceuticals completed the transaction.
Champignon Brands Inc. (CSE:SHRM) is focused on a mushroom-to-market strategy by offering a range of teas, that make use of functional mushrooms to offer entry-level exposure to the burgeoning boom in mushroom products. Champignon is committed to cultivating and distributing artisanal medical mushrooms and the CPGs derived from those mushrooms. Champignon Brands recently completed its initial public offering of more than 18 million common shares at a price of C$0.15 per share for total gross proceeds of more than $2.8 million. The company's common shares were listed on the Canadian Securities Exchange beginning February 27, 2020. After being halted pending completion of the IPO, the common shares resumed trading on the CSE on March 2, 2020, under the symbol SHRM. The company is also in the process of securing a listing in Germany as it seeks to establish an early presence in both North America and Europe. Roadman Investments Corp. (TSX-V:LITT) is a Canadian-listed venture capital firm that recently invested in Champignon Brands, a British Columbia-based craft mushroom distributor with plans to expand into psilocybin mushrooms.
Companies conducting research on psychedelic medications have caught the attention of cannabis investors, so Psychedelics could become the next big investing opportunity in 2020. There is not a lot of information out there on psychedelic stocks, but a few groups on Twitter seem to provide some insight. Here are just a few @MAPS, @PsyTechSummit, @PspacePship, @TheTripReport1, @InvestmentPsych, @ShroomStreet, and @PsychedelicSto7. The research into psychedelics has shown amazing promise. Unlike cannabis, it is legal for companies to do this kind of research in the United States. Other companies will definitely come into the fray, but these are just a few of the companies in the sector early. There is always the possibility larger cannabis companies like Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), OrganiGram Holdings, Inc. (NASDAQ:OGI), Amyris Inc. (AMRS) , Tilray Inc. (NASDAQ:TLRY), and Aurora Cannabis (NYSE:ACB) could enter the market.
<<<
Name | Symbol | % Assets |
---|---|---|
Cybin Inc Ordinary Shares | CYBN.NE | 9.69% |
Mind Medicine Inc Ordinary Shares | MMED.NE | 9.65% |
Seelos Therapeutics Inc | SEEL | 5.67% |
Relmada Therapeutics Inc | RLMD | 5.37% |
ATAI Life Sciences NV | ATAI | 4.98% |
Gh Rsrch | GHRS | 4.97% |
Alkermes PLC | ALKS | 4.78% |
Vistagen Therapeutics Inc | VTGN | 4.68% |
Bright Minds Biosciences Inc Ordinary Shares | DRUG.CN | 4.66% |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |